title: Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy.
abstract: Severe putamen dopamine depletion characterizes Parkinson's disease (PD) and multiple system atrophy (MSA). The extent of the depletion is greater than can be accounted for by loss of nigrostriatal dopaminergic terminals alone. We used putamen tissue levels and ratios of cysteinyl and parent catechols to explore possible denervation-independent abnormalities of dopamine synthesis and fate in PD and MSA. 5-S-Cysteinyldopa (Cys-DOPA) is produced from spontaneous oxidation of DOPA and 5-S-cysteinyldopamine (Cys-DA) from spontaneous oxidation of DA.
  
  
  
  Post-mortem putamen tissue samples from 17 PD and 25 MSA patients and 30 controls were assayed for endogenous catechols including DA, its cytoplasmic metabolites (Cys-DA, 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxyphenylethanol, and 3,4-dihydroxyphenylacetaldehyde), and tyrosine hydroxylation products proximal to DA (DOPA and Cys-DOPA).
  
  
  
  The PD and MSA groups did not differ in mean values of parent or cysteinyl catechols, and the data for the two groups were lumped. In the patients an index of vesicular storage of DA (the ratio of DA to the sum of its cytoplasmic metabolites) averaged 54% of control (p = 0.001), and an index of L-aromatic-amino-acid decarboxylase (LAAAD) activity (the ratio of DA and the sum of its cytoplasmic metabolites to the sum of DOPA + Cys-DOPA) averaged 21% of control (p < 0.0001). An index of innervation (the sum of DOPA + Cys-DOPA) averaged 63% of control (p = 0.01).
  
  
  
  Based on patterns of parent and cysteinyl catechols in putamen, PD and MSA involve decreased vesicular uptake and decreased LAAAD activity in the residual dopaminergic terminals. The combination seems to contribute importantly to dopamine depletion in these diseases.
authors.affiliation: Clinical Neurocardiology Section, CNP/DIR/NINDS/NIH, Bethesda, MD 20892-1620, USA. Electronic address: goldsteind@ninds.nih.gov.
authors.forename: David S
authors.initials: DS
authors.lastname: Goldstein
authors.affiliation: Clinical Neurocardiology Section, CNP/DIR/NINDS/NIH, Bethesda, MD 20892-1620, USA.
authors.forename: Patti
authors.initials: P
authors.lastname: Sullivan
authors.affiliation: Clinical Neurocardiology Section, CNP/DIR/NINDS/NIH, Bethesda, MD 20892-1620, USA.
authors.forename: Courtney
authors.initials: C
authors.lastname: Holmes
authors.affiliation: University of Miami Miller School of Medicine, Miami, FL 33136, USA.
authors.forename: Deborah C
authors.initials: DC
authors.lastname: Mash
authors.affiliation: Clinical Neurocardiology Section, CNP/DIR/NINDS/NIH, Bethesda, MD 20892-1620, USA.
authors.forename: Irwin J
authors.initials: IJ
authors.lastname: Kopin
authors.affiliation: Chaim Sheba Medical Center, Tel Ha-Shomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Yehonatan
authors.initials: Y
authors.lastname: Sharabi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003714:Denervation / Q000639:trends; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000378:metabolism* / Q000473:pathology; D010300:Parkinson Disease / Q000378:metabolism* / Q000473:pathology; D011699:Putamen / Q000378:metabolism* / Q000473:pathology
chemical_list: D004298:Dopamine
keywords: Cysteinyl-DOPA; Cysteinyl-dopamine; Multiple system atrophy; Parkinson’s disease